Key HighlightsNovo Nordisk has entered into a partnership with Orbis Medicines valued at up to $1.4 billion for drug developmentThe collaboration focuses on creating oral alternatives for cardiometabolic conditions now managed with injectionsOrbis will leverage its artificial intelligence-driven nGen technology to engineer oral macrocycle medicationsThe pharmaceutical giant will acquire an equity stake in the privately owned Orbis companyEarly-stage research shows macrocycle compounds achieving oral bioavailability rates reaching 18%On Thursday, Novo Nordisk (NVO) revealed a strategic collaboration with Danish biotechnology firm Orbis Medicines, establishing a drug discovery and licensing agreement potentially worth $1.4 billion. The initiative centers on creating oral medication options for cardiometabolic disorders.Novo Nordisk A/S, NVOThis strategic alliance addresses medical conditions presently requiring injectable medications. The companies aim to transform these injection-based treatments into convenient oral formulations that patients can take by mouth.Leveraging its proprietary nGen platform powered by artificial intelligence, Orbis will focus on identifying macrocycles—distinctive ring-structured molecular compounds. These molecules hold promise for engaging therapeutic targets that conventional small-molecule pharmaceuticals struggle to address.According to Orbis CEO Morten Graugaard, the company’s laboratory-created macrocycles have demonstrated oral bioavailability levels as high as 18% during early research phases. This metric indicates the percentage of an ingested drug that successfully enters systemic circulation.“Our partnership with Novo creates a pathway to develop a next-generation portfolio of oral therapies targeting cardiometabolic conditions,” Graugaard stated.Financial Terms and InvestmentThe partnership encompasses initial payments, milestone-based compensation tied to development and commercialization achievements, plus tiered royalty structures on eventual product revenues. Complete financial details regarding the $1.4 billion valuation remain undisclosed.Novo Nordisk plans to take a strategic ownership position in Orbis. The exact investment amount has not been publicly shared by either organization.This partnership complements Novo’s established oral peptide delivery system utilizing SNAC technology. The pharmaceutical company obtained this capability through its 2020 acquisition of Emisphere Technologies, a U.S.-based drug delivery specialist.A representative from Novo confirmed the organization’s commitment to advancing innovation in oral drug delivery through combined internal development efforts and strategic external alliances.Industry Momentum for Oral MacrocyclesThis agreement emerges amid expanding pharmaceutical industry interest in oral macrocyclic therapeutics.Johnson and Johnson (JNJ) secured FDA clearance in March for Icotyde, an orally administered macrocyclic peptide treating plaque psoriasis. Several months later in July, Merck (MRK) obtained approval for Lipfendra, an oral macrocyclic peptide designed to reduce cholesterol levels.Headquartered in Copenhagen, Orbis positions its nGen technology as purpose-built for accelerating macrocycle drug candidate identification through machine learning capabilities.The multi-target nature of this collaboration enables both organizations to pursue opportunities spanning multiple therapeutic areas within cardiometabolic medicine, rather than concentrating exclusively on individual compounds or specific conditions.Novo has provided limited commentary on how this partnership integrates with its comprehensive development portfolio, noting primarily that it extends the company’s ongoing oral medication delivery research.Following Thursday’s announcement, NVO stock attracted heightened investor attention, with market participants evaluating the potential for this collaboration to diversify Novo’s product pipeline beyond its established injectable GLP-1 therapeutic franchise.The post Novo Nordisk (NVO) Stock: Pharma Giant Inks $1.4B Partnership With Orbis for AI-Driven Oral Therapies appeared first on Blockonomi.